Cue Biopharma, Inc.
CUE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001645460
In the last 90 days, Cue Biopharma, Inc. insiders filed 0 open-market purchases and 5 sales; 50 institutions reported holding it in 13F filings for Q2 2026, worth $52.2M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:49 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $26.6M (96.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2026 | Mar 31, 2025 | – | – | – |
| Revenue | $27.5M | $9.29M | $5.49M | $1.25M | $14.9M |
| Operating expenses | $54.0M | $50.8M | $57.6M | $54.5M | $58.7M |
| Research and development | $37.7M | $36.3M | $40.8M | $38.6M | $41.3M |
| Selling, general and administrative | $16.2M | $14.6M | $16.7M | $16.2M | $17.3M |
| Operating income | -$26.6M | -$41.5M | -$52.1M | -$53.2M | -$43.7M |
| Interest expense | $100.0K | $100.0K | $130.0K | – | – |
| Income tax | $500.0K | – | – | $0 | $495.0K |
| Net income | -$26.6M | -$40.7M | -$50.7M | -$53.0M | -$44.2M |
| EPS, basic | $-0.28 | $-0.72 | $-1.11 | $-1.49 | – |
| EPS, diluted | $-0.28 | $-0.72 | $-1.11 | $-1.49 | – |
| Weighted shares, basic | 94.7M | 56.3M | 45.8M | 35.6M | – |
| Weighted shares, diluted | 94.7M | 56.3M | 45.8M | 35.6M | – |
| Margins and growth | |||||
| Operating margin | -96.7% | -446.9% | -949.9% | -4274.3% | -292.6% |
| Net margin | -96.9% | -438.0% | -924.1% | -4257.1% | -295.6% |
| Revenue growth, year over year | +195.7% | +69.2% | +340.9% | −91.7% | +373.7% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2026 | Mar 31, 2025 | – | – | – |
| Cash and equivalents | $27.1M | $22.5M | $48.5M | $51.6M | $64.4M |
| Accounts receivable | $5.55M | $945.0K | $1.70M | $57.3K | $3.14M |
| Total current assets | $37.0M | $25.1M | $51.5M | $77.2M | $68.5M |
| Property, plant and equipment | $241.0K | $471.0K | $795.0K | $1.50M | $2.11M |
| Total assets | $42.2M | $32.2M | $61.5M | $91.3M | $83.4M |
| Accounts payable | $3.95M | $2.82M | $3.50M | $2.73M | $2.59M |
| Short-term debt | – | $37.0K | $37.0K | $74.0K | – |
| Total current liabilities | $13.5M | $13.7M | $17.1M | $11.5M | $12.8M |
| Long-term debt | – | $0 | $4.20M | $8.03M | – |
| Total liabilities | $15.8M | $14.7M | $24.4M | $25.6M | $17.9M |
| Shareholders' equity | $26.4M | $17.5M | $37.1M | $65.7M | $65.5M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 16, 2026 | Mar 31, 2025 | – | – | – |
| Operating cash flow | -$21.7M | -$36.3M | -$40.0M | -$41.8M | -$38.8M |
| Capital expenditures | $177.0K | $66.0K | $0 | $170.7K | $913.0K |
| Free cash flow | -$21.9M | -$36.4M | -$40.0M | -$42.0M | -$39.8M |
| Depreciation and amortization | $958.0K | $397.0K | $556.0K | $922.2K | $1.26M |
| Stock-based compensation | $4.74M | $6.85M | $8.18M | $9.50M | $11.5M |
| Share buybacks | – | – | $0 | $199.9K | $750.2K |
| Investing cash flow | $75.0K | $32.0K | $25.0M | -$24.6M | $9.11M |
| Financing cash flow | $26.3M | $10.2M | $11.9M | $53.7M | $19.2M |
| Net change in cash | $4.68M | -$26.1M | -$3.10M | -$12.8M | -$10.5M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 17.3% | 73.7% | 149.0% | 762.6% | 77.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Aug 12, 2026 | 7.26M | −90.5% | SEC |
| May 12, 2026 | 4.05M | −94.6% | SEC |
| Mar 13, 2026 | 97.7M | +58.0% | SEC |
| Nov 7, 2025 | 78.7M | +24.3% | SEC |
| Aug 8, 2025 | 76.8M | +58.0% | SEC |
| May 8, 2025 | 75.3M | +54.9% | SEC |
| Mar 27, 2025 | 61.8M | +27.1% | SEC |
| Nov 10, 2024 | 63.4M | +40.4% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.